This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN

Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN
Reviewed by Anjali Gupta

1 October 2014 | Anjali Gupta | EYE - Cornea, EYE - General | OSSN, chemotherapy, ocular oncology, ocular surface tumours

Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly reduces the rate of recurrence. This paper presented a long-term follow-up of two prospective non-comparative interventional case series examining recurrence and side-effect rates in patients receiving 5-FU (fluorouracil) or mitomycin C (MMC) as adjuvants to surgical excision of localised OSSN. Eighty-nine eyes were included in the 5-FU group and 64 eyes were included in the MMC group. All patients underwent complete superficial dissection of the lesion with a 2mm margin. All lesions in the 5-FU group had cryotherapy applied intraoperatively, however, cryotherapy was not available in 18.7% of cases in the MMC arm. Median follow-up was 33.6 months in the 5-FU arm and 57.9 months in the MMC arm. There were no recurrences in the MMC arm and one recurrence in the 5-FU arm. This case of recurrence was in an incompletely excised CIN III lesion with an incomplete course of adjuvant 5-FU therapy. Overall, side-effects were encountered in 69% of 5-FU cases compared with 41% of MMC cases. Sixty-two percent of 5-FU cases experienced lid toxicity vs. 0% of MMC cases. No 5-FU cases experienced allergy vs. 28% of MMC cases. Ten percent of patients in the 5-FU group developed epiphora, compared with 17% in the MMC group. The authors concluded that recurrence is rare when adjuvant 5-FU or MMC is used in surgically excised localised OSSN and although side-effects are common, the majority are transient and rarely limit compliance. 

Long-term outcomes after adjunctive topical 5-fluorouracil or mitomycin C for the treatment of surgically excised, localised ocular surface squamous neoplasia.
Bahrami B, Greenwell T, Muecke S.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
2014;42:317-22.
Share This
CONTRIBUTOR
Anjali Gupta

Birmingham and Midland Eye Centre, Birmingham, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency